Preview

Воспаление жировой ткани. Часть 6. Действие медикаментозных средств.

https://doi.org/10.14341/probl201258167-73

Аннотация

Представлены данные о влиянии салицилатов, препаратов, использующихся при ожирении, препаратов для лечения сахарного диабета, артериальной гипертонии, а также атеросклероза на функциональное состояние жировой ткани и воспалительный процесс в ней. Многие из них обладают противовоспалительным действием, причем реализующимся различными путями. Пока нет медикаментозных средств лечения воспаления жировой ткани. Однако противовоспалительное действие ряда препаратов может учитываться при лечении различных заболеваний с сопутствующим ожирением и подозрением на воспаление жировой ткани.

Об авторе

V Shvarts



Список литературы

1. Шварц В. Воспаление жировой ткани (часть 1). Морфологические и функциональные проявления. Пробл эндокринол 2009; 4: 44-49.

2. Шварц В. Воспаление как фактор патогенеза инсулинорезистентности и сахарного диабета 2-го типа. Тер арх 2009; 10: 74-80.

3. Шварц В. Воспаление жировой ткани и атеросклероз. Кардиология 2009; 12: 80-86.

4. Westerink J., Visseren Frank L.J. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011; 10: 13-21.

5. Шварц В. Жировая ткань как эндокринный орган. Пробл эндокринол 2009; 1: 38-44.

6. Шварц В. Жировая ткань как орган иммунной системы. Цитокины и воспаление 2009; 8: 4: 3-10.

7. Koska J., Ortega E., Bunt J.C., Gasser A., Impson J., Hanson R.L. et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52: 385-393.

8. Goldfine A.B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J. et al. Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes. Clin Transl Sci 2008; 1: 36-43.

9. Hovens M.M., Snoep J.D., Groeneveld Y., Frolich M., Tamsma J.T., Huisman M.V. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabet Obes Metab 2008; 8: 668-674.

10. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J. et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201: 1205-1215.

11. Шварц В. Адипонектин: патофизиологические аспекты. Патол физиол и эксперимент тер 2009; 3: 34-38.

12. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.

13. Bougoulia M., Triantos A., Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens ) 2006; 5: 259-269.

14. Kim D.M., Yoon S.J., Ahn C.W., Cha B.S., Lim S.K., Kim K.R. et al. Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabet Res Clin Pract 2004; 66: Suppl 1: S139-S144.

15. James W.P., Caterson I.D., Coutinho W., Finer N., Van Gaal L.F., Maggioni A.P. et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.

16. Шварц В. Применение римонабанта при сахарном диабете 2-го типа. Пробл эндокринол 2008; 6: 32-38.

17. Bullkao C., Ribeiro-Filho F.F., Sanudo A. et al. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007; 7: 219-224.

18. Hannori Y., Suzuki K., Hattori S. et al. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006; 47: 1183-1188.

19. Mahrouf M., Ouslimani N., Peynet J. et al. Metformin reduced angiotensin-mediated intracellular production of reactive oxygen in endothelial cells through the inhibition of protein kinase C. Biochim Pharm 2006; 72: 176-183.

20. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.

21. Ialenti A. et al. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol Pharmacol 2005; 67: 1620-1628.

22. Шварц В. Применение ингибиторов дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа. Пробл эндокринол 2008; 54: 4: 39-45.

23. Shirakawa J., Fujii H., Ohnuma K. et al. Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice. Diabetes 2011; 60: 1246-1257.

24. Ferreira L., Teixeira-de-Lemos E., Pinto F. et al. Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat). Mediators Inflamm 2010; 29: 159-167.

25. Ta N.N., Li Y., Schuyler C.A., Lopes-Virella M.F., Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010; 213: 429-435.

26. Yin W.H., Jen H.L., Chen L.W. et al. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment in plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabet Metab 2006; 32: 229-235.

27. Kastelein J.P., Akdim F., Stroes E.S. et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med 2008; 358: 14: 1431-1443.

28. Abe M., Matsuda M., Kobayashi H., Miyata Y., Nakayama Y., Komuro R. et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 871-877.

29. Takagi T., Matsuda M., Abe M., Kobayashi H., Fukuhara A., Komuro R. et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008; 196: 114-121.

30. Forst T., Pfutzner A., Lubben G., Weber M., Marx N., Karagiannis E. et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007; 56: 491-496.

31. Kostapanos M.S., Derdemezis C.S., Filippatos T.D., Milionis H.J., Kiortsis D.N., Tselepis A.D. et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 578: 249-252.

32. Rigamonti E., Chinetti-Gbaguidi G., Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008; 28: 1050-1059.

33. Oki K., Koide J., Nakanishi S., Nakashima R., Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocrin J 2007; 54: 431-435.

34. Saiki A., Ohira M., Endo K., Koide N., Oyama T., Murano T. et al. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009; 58: 708-713.

35. Tsuchiya K., Yoshimoto T., Hirono Y., Tateno T., Sugiyama T., Hirata Y. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006; 291: E771-E778.

36. Mathai M.L., Naik S., Sinclair A.J., Weisinger H.S., Weisinger R.S. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 2008; 32: 1576-1584.

37. Janke J., Schupp M., Engeli S., Gorzelniak K., Boschmann M., Sauma L. et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006; 24: 1809-1816.

38. Derosa G., Cicero A.F., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N. et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29: 849-856.

39. Shimabukuro M., Tanaka H., Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007; 25: 841-848.

40. Cruickshank J.M. Are we misunderstanding beta-blockers. Int J Cardiol 2007; 120: 10-27.

41. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 142-146.

42. Celik T., Iyisoy A., Kursaklioglu H., Kardesoglu E., Kilic S., Turhan H. et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.

43. Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group. Cardiovasc Drugs Ther 2000; 14: 67-75.

44. Hansen P.R., Rieneck K., Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett 2004; 91: 87-91.

45. Lamounier-Zepter V., Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 2006; 8: 30-34.

46. Guo C., Ricchiuti V., Lian B.Q., Yao T.M., Coutinho P., Romero J.R. et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.

47. Hirata A., Maeda N., Hiuge A., Hibuse T., Fujita K., Okada T. et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172.

48. Matsumoto S., Takebayashi K., Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 2006; 55: 1645-1652.


Для цитирования:


. Воспаление жировой ткани. Часть 6. Действие медикаментозных средств. Проблемы Эндокринологии. 2012;58(1):67-73. https://doi.org/10.14341/probl201258167-73

For citation:


Shvarts V.I. Inflammation of adipose tissue (Part 6). The effects of medicamental preparations. Problems of Endocrinology. 2012;58(1):67-73. (In Russ.) https://doi.org/10.14341/probl201258167-73

Просмотров: 30


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)